

Tricks to translating TB transcriptomics

Armin Deffur^{1,2}, Robert J. Wilkinson^{1,2,3,4}, Anna K. Coussens¹

¹Clinical Infectious Diseases Research Initiative, Institute of Infectious Disease and Molecular Medicine, ²Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Observatory, 7925, South Africa; ³The Francis Crick Institute, Mill Hill Laboratory, London, NW7 1AA, UK; ⁴Department of Medicine, Imperial College London, W2 1PG, UK

Correspondence to: Anna K. Coussens, PhD. Clinical Infectious Diseases Research Initiative, Institute of Infectious Disease & Molecular Medicine, University of Cape Town, Anzio Rd, Observatory, 7925, South Africa. Email: anna.coussens@uct.ac.za.

Abstract: Transcriptomics and other high-throughput methods are increasingly applied to questions relating to tuberculosis (TB) pathogenesis. Whole blood transcriptomics has repeatedly been applied to define correlates of TB risk and has produced new insight into the late stage of disease pathogenesis. In a novel approach, authors of a recently published study in *Science Translational Medicine* applied complex data analysis of existing TB transcriptomic datasets, and *in vitro* models, in an attempt to identify correlates of protection in TB, which are crucially required for the development of novel TB diagnostics and therapeutics to halt this global epidemic. Utilizing latent TB infection (LTBI) as a surrogate of protection, they identified IL-32 as a mediator of interferon gamma (IFN γ)-vitamin D dependent antimicrobial immunity and a marker of LTBI. Here, we provide a review of all TB whole-blood transcriptomic studies to date in the context of identifying correlates of protection, discuss potential pitfalls of combining complex analyses originating from such studies, the importance of detailed metadata to interpret differential patient classification algorithms, the effect of differing circulating cell populations between patient groups on the interpretation of resulting biomarkers and we decipher weighted gene co-expression network analysis (WGCNA), a recently developed systems biology tool which holds promise of identifying novel pathway interactions in disease pathogenesis. In conclusion, we propose the development of an integrated OMICS platform and open access to detailed metadata, in order for the TB research community to leverage the vast array of OMICS data being generated with the aim of unraveling the holy grail of TB research: correlates of protection.

Keywords: Biomarker; tuberculosis (TB); protective immunity; correlates of risk; microarray; systems biology

Submitted Apr 09, 2015. Accepted for publication Apr 09, 2015.

doi: 10.3978/j.issn.2305-5839.2015.04.12

View this article at: <http://dx.doi.org/10.3978/j.issn.2305-5839.2015.04.12>

Introduction

In 2013, an estimated 9.0 million people developed tuberculosis (TB) and 1.5 million died from the disease (1). Despite ongoing research efforts and ever-increasing knowledge of how *Mycobacterium tuberculosis* (*M.tb*) interferes with the human immune response, we are still far from developing the diagnostic and therapeutic approaches that would reduce the severity of this global epidemic. Vaccines form the cornerstone of potential eradication strategies of TB, yet the biological factors that provide protection from disease progression (so-called biological correlates of protection), which would assist design and testing of new vaccine candidates are lacking. A better

understanding of natural protective immunity to TB would facilitate these attempts. Following inhalation of *M.tb* bacilli, latent TB infection (LTBI) is the most common outcome. It is considered that in LTBI the growth of the bacilli is contained by the coordinated host innate and adaptive immune response, preventing disease progression, but there is failure to completely eradicate all organisms, such that an underlying asymptomatic infection persists. This makes LTBI a particularly useful model system for the discovery of protective correlates.

In the last 8 years, 15 transcriptomic studies have been published that use whole-genome gene expression microarrays in an effort to gain a broader understanding of the human response to *M.tb* infection, during various

stages of pathogenesis and treatment (Figure 1). These studies have generally characterized the whole blood response, although the papers by Berry *et al.* and Bloom *et al.* (5,12) also investigated expression profiles on separated cell populations to delineate the effect of varying cell number and cell activation on the whole blood response. These studies provide evidence for correlates of risk of active TB, and have been remarkably concordant in their findings. In particular, they reveal an important role for type-I interferon signaling and neutrophil influx in disease pathogenesis, driving new areas of TB research. Moreover, they provide evidence that LTBI actually represents a spectrum of disease states: the whole blood signature of some LTBI cases clustered with those with active TB, suggesting these participants may be at risk of developing disease. The microarray data on which these studies are based have mostly been deposited in public databases (Figure 1), but generally the associated patient metadata is incomplete or unavailable. This significantly limits the utility of the data as the primary research can often not be reproduced. Without such detailed metadata, it can be challenging to meaningfully combine datasets in meta-analyses, even once the challenge of combining data from different platforms has been overcome. Moreover, while these studies provide evidence for blood biomarkers to diagnose active TB and monitor treatment, they have shed less light on correlates of protection against disease.

In a recent paper (17) published in *Science Translational Medicine*, Montoya *et al.* used an interesting combination of informatics and additional *in vitro* experiments to do just that. The novel strategy employed by the authors consisted of three components. Firstly, an idealized monocellular *in vitro* system was studied using transcriptomic approaches. The authors identified genes that correlate with defense response in differentiating macrophages, whose phenotype was previously associated with *M.tb* control (18,19). Hypotheses resulting from the first section were then tested in a second set of *in vitro* experiments. The final step involved further informatics analyses of existing human TB transcriptomic datasets to identify genes up-regulated in LTBI cases or which are decreased during active TB and increase during TB therapy. The three components were then integrated by determining the overlap of the genes sets from the *in vitro* and *in vivo* transcriptomic analyses in order to identify genes representing potential biomarkers of protective immunity. Via this method Montoya *et al.* identified IL-32 as a mediator of interferon gamma (IFN γ)-vitamin D mediated antimicrobial activity, and a marker of LTBI.

The importance of sample and patient characterization

While this novel approach yielded interesting candidate biomarkers of LTBI, there are a number of factors which must be taken into account to ensure this method yields translatable outcomes for understanding protective immunity (Table 1). Montoya *et al.*'s approach critically depends on how they differentiated and purified their *in vitro* cell populations, the differing proportions of circulating cell subsets between patient groups, and, critically, how they (or rather the authors of the original datasets) classified individuals as having LTBI.

Diagnosis of LTBI relies on the measurement of the adaptive response by tuberculin skin test (TST) or interferon-gamma release assay (IGRA), performed on whole blood samples. Thus, these tests only inform us about immune memory, not current infection status; they cannot differentiate whether an individual eradicated the infection, either via the innate response or with help from the adaptive response. It has become clear that reliance on TST or IGRA-based classification approaches to define LTBI can result in very specific patient cohorts with different, and limited, disease phenotypes. Moreover, studies use different combinations of these tests to define LTBI (Figure 1). Thus better methods for defining LTBI are required; in particular, a marker for current *M.tb* infection, not based on immune sensitization. PET/CT imaging is one such approach that holds promise (20). When using LTBI as a model of protective immunity, it is therefore imperative that results are interpreted in the context of how patient groups were actually defined, particularly when an immune measure is used for classification; otherwise findings may be biased towards a specific phenotype. Moreover, outcomes need to be framed in the context of their derivation and not given a broad implication until validated on additional patient cohorts.

The cellular composition of samples from which RNA was extracted for these analyses is the second vital component to interpreting the results from transcriptomic studies. Whole-blood signatures are highly influenced by differing proportions of circulating cell populations, which obviously differ by disease states. Many of the differences in T cell transcripts identified between individuals with TB and healthy controls, identified by Berry *et al.* (5), were ascribed to decreased circulating lymphocyte numbers in TB patients, rather than functional differences in cells. TB is known to be a

| Studies | | | | | Classes: <i>in vivo</i> | Inclusion criteria and cutoffs | | | | | | | | | | N | | | | | | | | | |
|---|----------------------------|---|----------------------------------|-----------------------------|---|--------------------------------|-------------------|------------------------|-------------------|----------|--------------------------|-------------------------------|--------------|----------------------|----------------------|--------------------------------|-----------------------|-----------|---|----|----|----|----|----|-----|
| Study | Sample | Platform | GEO/ArrayExpress ID | Country | Classes | HIV-1 status | Prior TB | Contact with active TB | TST | IGRA-QFT | IGRA-other/not specified | Compatible symptoms and signs | Sputum smear | Sputum/BAL culture + | Radiographic disease | Non-respiratory sample culture | Alternative diagnosis | Histology | | | | | | | |
| Mistry <i>et al.</i> (2) 2007 | Blood | Two custom arrays: 50,000 clones (Invitrogen) and 8,000 genes | Not deposited | South Africa | Active PTB | - | | | | | | | | + | | | | | | 10 | | | | | |
| | | | | | LTBI | - | - | | >15 mm | | | | | | | | | | | | 10 | | | | |
| | | | | | Cured TB (1 st episode, disease free ≥18 months) | - | | | | | | | | | | | - | | | | | | 10 | | |
| | | | | | Recurrent TB (2-3 episodes, disease free ≥18 months) | - | | | | | | | | | | | - | | | | | | 10 | | |
| Jacobsen <i>et al.</i> (3) 2007 | PBMC | Custom Agilent (8,033 genes) | GSE6112 | Germany | Active PTB (<6 weeks of rx) | - | | | | | | | | + | + | ± | | | | 9 | | | | | |
| | | | | | LTBI | - | | + | >10 mm | | | | | | | | | | | | | 9 | | | |
| Kim <i>et al.</i> (4) 2010 | Tissue | Affymetrix Human XP3 | GSE20050 | South Africa | PTB granuloma (prob MDR) | | | | | | | | | | | | | | + | 5 | | | | | |
| | | | | | Healthy lung | | | | | | | | | | | | | | | | + | 2 | | | |
| Berry <i>et al.</i> (5) 2010 | Blood | Illumina HT12 v3 | GSE19439 GSE19444 GSE19435 | UK | Active PTB | | | | | | | | | + | | | | | | | 34 | | | | |
| | | | | | LTBI (TST and IGRA) | | | | ≥6 mm/ ≥15 mm* | + | | | | | | | | | | | | | 38 | | |
| | | | | | Healthy | | | | ≤6 mm/ ≤15 mm* | - | | | | | | | | | | | | | | 24 | |
| | Purified leukocytes | GSE19442 | South Africa | Active PTB | - | | | | | | | | | | + | | | | | | 20 | | | | |
| | | | | LTBI (IGRA) | - | | | | + | | | | | | | | | | | | | 31 | | | |
| | | | | Active PTB | | | | | | | | | | | | | + | | | | | | 7 | | |
| GSE19443 | UK | Active PTB | | | | | | | | | | | | | | | | | | | 4 | | | | |
| | | Healthy | | | | | ≤6 mm/ ≤15 mm* | - | | | | | | | | | | | | | | | | | |
| Maertzdorf <i>et al.</i> (6) 2011 | Blood | Agilent Human 4x44k | GSE28623 | Gambia | Active PTB | - | | | | | | | | + | | + | | | | | 46 | | | | |
| | | | | | LTBI | - | | + | ≥10 mm | | | | | | | | | | | | | 25 | | | |
| | | | | | Healthy | - | | | 0 mm | | | | | | | | | | | | | | | 37 | |
| Maertzdorf <i>et al.</i> (7) 2011 | Blood | Agilent 2 colour | GSE25534 | South Africa | Active PTB | - | | | | | | | | | ± | + | + | | | | 33 | | | | |
| | | | | | LTBI | - | | + | + | | | | | | - | - | - | | | | | | 34 | | |
| | | | | | Healthy | - | | | - | | | | | | | | | | | | | | | 9 | |
| Lesho <i>et al.</i> (8) 2011 | PBMC | Affymetrix HG 133 Plus 2.0 | Not deposited | USA | Active PTB | - | | | | | | | | + | + | + | | | | | 5 | | | | |
| | | | | | LTBI (documented conversion) | - | | | ≥15 mm | | | | | | | | | | | | | | 6 | | |
| | | | | | Healthy BCG vaccinated | - | | | <15 mm | | | | | | | | | | | | | | | 5 | |
| | | | | | Healthy BCG unvaccinated | - | | | 0 mm | | | | | | | | | | | | | | | | 7 |
| Bloom <i>et al.</i> (9) 2012 | Blood | Illumina HT12v4 | GSE40553 | South Africa | Active PTB | - | | | | | | | | + | | | | | | | 29 | | | | |
| | | | | UK | LTBI (IGRA) | - | | | | + | | | | | | | | | | | | 38 | | | |
| Ottenhoff <i>et al.</i> (10) 2012 | Blood | IlluminaRef-8 v3 | GSE56153 | Indonesia | Active PTB | - | | | | | | | + | + | + | | | | | | 23 | | | | |
| | | | | | Not active PTB | - | | | | | | | | | | | | | | | | | 23 | | |
| Maertzdorf <i>et al.</i> (11) 2012 | Blood | Agilent Human 4x44k | GSE34608 | Germany | Active PTB | - | | | | | | | | | | | | | | | 8 | | | | |
| | | | | | Sarcoidosis | - | | | | | | | | | | | | | | | | | 18 | | |
| | | | | | LTBI (IGRA) | - | | | | | + | | | | | | | | | | | | 4 | | |
| | | | | | Healthy control | - | | | | | | | | | | | | | | | | | | 14 | |
| Bloom <i>et al.</i> (12) 2013 | Blood, purified leukocytes | Illumina HT12v4 | GSE42834 | UK, France | Active PTB | - | | | | | | | | | + | | | | | | 35 | | | | |
| | | | | | Sarcoidosis | - | | | | | | | | | | | | + | | | | | 61 | | |
| | | | | | Pneumonia | - | | | | | | | | | | | + | | | | | | | 14 | |
| | | | | | Lung cancer | - | | | | | | | | | | | | | + | | | | | 16 | |
| | | | | | Healthy control | - | | | | | | | | | | | | | | | | | | | 113 |
| Cliff <i>et al.</i> (13) 2013 | Blood | Affymetrix U133 Plus 2.0 | GSE31348, GSE36238 | South Africa | Active PTB | - | | | | | | | + | | + | | | | | 36 | | | | | |
| Kaforou <i>et al.</i> (14) 2013 | Blood | Illumina HT12v4 | GSE37250 | South Africa, Malawi | Active PTB | - | | | | | | | | + | | + | | | | | 97 | | | | |
| | | | | | Active PTB | + | | | | | | | | | | | | | | | | | 97 | | |
| | | | | | LTBI (TST and IGRA) | - | | | | ≥10 mm | + | - | - | | | | | | | | | | | 83 | |
| | | | | | LTBI (TST and IGRA) | + | | | | ≥25 mm | + | - | - | | | | | | | | | | | | 84 |
| | | | | | OD | - | | | | | | | | | | | | | | | | | ± | | 83 |
| OD | + | | | | | | | | | | | | | | | | | ± | | 92 | | | | | |
| Cai <i>et al.</i> (15) 2014 | PBMC | Affymetrix U133 Plus 2.0 | GSE54992 | China | Active PTB | | | | | | | | | ± | ± | ± | ± | | | | 9 | | | | |
| | | | | | LTBI (IGRA) | | | | | | | | | | | | | | | | | | 6 | | |
| | | | | | Healthy | | | | | | | | | | | | | | | | | | | 6 | |
| Anderson <i>et al.</i> (16) 2014 [†] | Blood | Illumina HT12v4 | GSE39941 | South Africa, Malawi, Kenya | Active TB culture + | - | | | | | | | | + | ± | ± | ± | ± | | | 97 | | | | |
| | | | | | Active TB culture + | + | | | | | | | | | | | | + | ± | ± | ± | | | 52 | |
| | | | | | Active TB culture - | - | | | | | | | | | | | | | | | | | ± | | 27 |
| | | | | | Active TB culture - | + | | | | | | | | | | | | | | | | | | | 17 |
| | | | | | LTBI (TST and/or IGRA) | - | | | | + | + | | | | | | | | | | | | | | 71 |
| | | | | | OD | - | | | | | | | | | | | | | | | | | | | |
| OD | + | | | | | | | | | | | | | | | | | | | | 97 | | | | |

Figure 1 Human sample types and patient group classification criteria in studies publishing novel TB transcriptomic data (2-16). [†], this study exclusively recruited children <15 years; all other studies recruited adults >18 years. *, if BCG vaccinated. LTBI data subsets highlighted in red were used in the study by Montoya *et al.* -, negative test result; +, positive test result; ±, test not essential for inclusion. BAL, bronchoalveolar lavage; IGRA, interferon-gamma release assay; LTBI, latent TB infection; MDR, multi-drug resistant TB; OD, other disease; PBMC, peripheral blood mononuclear cells; PTB, pulmonary tuberculosis; rx, treatment; TST, tuberculin skin test.

Table 1 Considerations for interpreting transcriptomic outputs based on inputs

| |
|--|
| Patient classification |
| Diagnostic criteria |
| TB diagnosis: sputum culture or smear, CXR, empiric |
| Latent TB: TST cut-off, IGRA, TB contact |
| Healthy controls: no TB exposure, asymptomatic, negative TST and IGRA |
| Population of origin |
| Genetic diversity |
| Environmental exposures (NTM, co-morbidity) |
| Differences in demographics (age, sex) |
| Disease severity |
| Duration of symptoms |
| Extent of disease |
| Pulmonary vs. extrapulmonary or disseminated |
| Treatment regimen |
| Duration of treatment prior to sampling |
| Sample composition |
| Single cell populations |
| Method of isolation |
| Method of differentiation |
| Measure of purity |
| Whole blood |
| Cellular composition |
| Separated cell subsets |
| Time and season of blood draw |
| <p>TB, tuberculosis; CXR, chest X-ray; TST, tuberculin skin test; IGRA, interferon gamma release assay; NTM, non-tuberculous mycobacteria.</p> |

disease of relative lymphopenia and neutrophilia, thus, it may be predictable that whole-blood from TB patients is dominated by a neutrophil-driven transcriptomic response. Moreover, extrapolating observations in blood to processes of disease pathogenesis occurring at the site of disease remain problematic. Although this comparison does identify biomarkers of TB disease, in comparison to someone who is healthy, what is actually required is a disease-specific signature. Thus, a more rigorous comparison should include a third group of individuals with similar symptoms but differing etiology. Three such studies have performed this (*Figure 1*), two comparing TB and sarcoidosis patients (11,12), another granulomatous

lung disease, and one comparing TB patients and respiratory symptomatics with other diagnoses (14). In their study, Bloom *et al.* found the signature of TB and sarcoidosis to cluster together, when compared to pneumonia and lung cancer, and both to be dominated by interferon-inducible transcripts. Thus, one must be extremely careful when conducting any transcriptomic study to ensure the interpretation of the differentially expressed genes are contextualized with regard to the disease states of the individuals, the effect of the disease state on the peripheral blood compartment and how it may relate to processes at the site of disease.

Finally, not only is it vital to acknowledge the effect of differing proportions of cell types in differing disease states, during a whole-blood comparison, but also the purity of an isolated cell population from *in vitro* or *ex vivo* analyses, when results are to be extrapolated to a particular cell type. Montoya *et al.* made particular note of this latter point, in relation to describing unexpected gene expression results from purified CD14⁺ monocyte cultures to the presence of potentially contaminating CD8 T cells. There must be consistency in how results are interpreted. If unexpected results are attributed to an unknown percentage of contaminating cells it can become difficult to ascribe other observations from the same data solely to the predominant cell population.

The paper by Montoya *et al.* is novel in its approach and is rich in data. But, to interpret the relevance of their findings, it is necessary to carefully examine the methods, both *in vitro* and the complex informatics that form the backbone of the authors' findings. Immunologically, the *in vitro* methods are logical and easy to follow; based on their previous finding that IL-15 differentiates monocytes into macrophages exhibiting an M1-like phenotype with antimycobacterial properties (18,19), they extracted RNA for microarrays (GEO accession GSE59184) from CD14⁺ selected monocytes (90% purity) derived from adherent peripheral blood mononuclear cells (PBMC) from healthy donors treated for 6 and 24 hours with IL-15, IL-4 and IL-10 (to generate M2-like macrophages) or media control. Weighted gene co-expression network analysis (WGCNA) was then applied to the data and forms the crux of understanding all informatics analyses conducted in this study. This systems biology approach has the potential to elucidate novel pathways of cellular interaction which is vital to our understanding the complex disease pathogenesis of TB; but to correctly interpret its output, an understanding of the methodology is required.

Translating modular analyses

The WGCNA algorithm identifies modules of co-expressed genes whose transcript abundance co-varies across samples by correlation and clustering analysis. For each module, a module eigengene (ME) is determined; this represents the first principal component of the expression data matrix for the module (a genes \times b samples). This ME summarizes the expression of the module in a single number, it does not represent one gene in the module, but all genes. Then the matrix of module eigengenes (m modules \times by b samples) and the matrix of phenotype variables (b samples \times p phenotypes) are correlated with a resulting m \times p correlation matrix. This matrix provides information on the association between modules and phenotype. In the Montoya *et al.* paper, only a single module (*MEblack*) is highlighted as biologically relevant, being the most positively correlated with IL-15 treatment; all other modules are excluded in further discussion. The black module is enriched for the gene ontology (GO) term “defense response” (48 genes out of 802 probes), and contains *IL32*. Next, 36 “myeloid defense genes” are defined, characterized as any of these 48 defense response genes expressed in resting myeloid cells, as determined from a preexisting transcriptional dataset (21). Interestingly the authors define *IL32* as myeloid-derived despite lymphoid cells being the predominant cells expressing it in their comparison of 24 gene-sets from resting cells. They further support the myeloid origin of *IL32* by reference to studies identifying its expression by monocytic cells following IFN γ , TLR4 or NOD2 activation; an alternate interpretation of this data is that *IL32* expression is induced by stimulation and not abundant in resting myeloid cells. Other “defense-response” genes were labeled myeloid-derived based on their informatics approach alone and it highlights the need for consistency in the interpretation and selection of candidate genes which become the focus of further analyses. The top interactions for these myeloid-defense genes were then visualized using the network visualization and analysis tool VisANT and consequently *IL32* was linked to the vitamin D antimicrobial pathway, via correlation with *CYP27B1* induction, which encodes the final enzyme needed to activate vitamin D.

Avoiding selective bias

While the authors elegantly demonstrate with subsequent *in vitro* silencing experiments that IL-32, reliant on vitamin D, is a downstream gene in the IFN γ antimicrobial pathway,

it would have been of interest to have more information about the module in which *IL32* was identified, including the gene list for *IL15black*, the fold-change of *IL32*, direction of induction of and its position in the list of genes regulated by IL-15. It is clear *IL32* is an important gene in this module, but there are others, which may also pose as potential correlates of protection. This is a fundamental issue researchers working with transcriptomic data now face; given a list of 100 interesting genes, what is the basis for further investigation? Supervised selection of genes may bias outcome and more high-throughput methods for robust validation and confirmation using *in vivo* systems is required. When researchers are selective, they must ensure their approach is transparent and reproducible. They must provide all gene lists which guided their selective approach, to ensure their outcomes are not biased and their findings are placed within the context of the greater gene regulation network(s).

The final section of the paper focuses on mining existing transcriptomic datasets from patients with active TB, LTBI or healthy controls, utilizing four of the 15 available studies (5,9,11,14). The overall approach is to identify genes that are more highly expressed in individuals with LTBI (diagnosed using a combination of TST, Quantiferon Gold and in-house IGRA assays) compared to those with either active TB or healthy controls (asymptomatic IGRA-negative). One of these studies (9) also investigated the transcriptional response during TB treatment, and was used to identify genes highly expressed in LTBI, which are low at TB diagnosis and increase during treatment. The previously identified *IL15black* module from the macrophage microarray experiments was then overlapped with the LTBI-high genes and with the one module from the response to treatment analysis, which was selected on the basis that it contains IL-32. Four other modules from the TB treatment data set actually show a more significant ME for genes which increase during treatment, but these do not contain IL-32 and are therefore not followed-up. Thus there remain many uninvestigated but interesting modules, which may provide further potential correlates of protection, but which were deprioritized in a somewhat self-fulfilling approach.

While it is clear that *IL32* has a role in antimicrobial immunity, there are two methodological issues which may arise in any TB OMICS study, which should heed caution to it being defined as a correlate of protective immunity, until further validation. Firstly, the immunological basis of LTBI diagnosis, secondly, the differences in cell populations

between healthy and disease individuals. As the LTBI group used in this study was defined by IGRA positivity, and thus their greater ability to produce IFN γ , it is potentially self-fulfilling that transcripts associated with the IFN- γ pathway, i.e., *IL32*, were identified to be more abundant in latent *vs.* healthy individuals. Moreover, *IL32*, which is predominantly expressed by lymphoid cells, is less abundant in active TB, a state of peripheral lymphopenia, and the increase in *IL32* during therapy is coincident with peripheral lymphocyte reconstitution. Thus, the lack of the marker in TB may merely be a reflection of the peripheral blood state of disease and not necessarily a functional defect resulting in loss of protective immunity. These issues highlight the importance of using non-immunological criteria for patient group classification and the need to adjust for differences in the cellular composition of samples compared between groups.

The future of TB OMICS

Translational Medicine increasingly relies on high-throughput data to inform hypothesis generation and system descriptions. While the generation of such data is becoming routine; increasingly complex informatics approaches are being utilized in order to optimally extract information from the data. Based on our interpretation, it is not clear that the approach used to identify correlates of protection from active TB was truly unsupervised, but rather semi-supervised and it appears that the study conclusions were to some extent self-fulfilling. Despite these limitations, such systems approaches to identify correlates of protection using existing data sets are useful, as is the use of transcriptomics to identify novel pathways of protection from *in vitro* cultures. For the informatics approaches to work best, higher-quality patient-level metadata is required for published transcriptomic datasets. Such information is crucial to account for differences in populations, disease presentation, *M.tb* exposure and underlying co-existent conditions (infections and non-communicable diseases). Ownership of such data and authorship of future manuscripts using this data may become complex. However, if we are to move towards utilizing the wealth of data accumulated over the last decade, in order to provide the crucial insights needed to advance TB research, this is a step researchers need to tackle.

To fully utilize the information from high-throughput OMICS approaches, there is the need to develop a platform for data integration. This should systematically capture all

information from transcriptomics, proteomics and detailed clinical phenotype data. There should be an emphasis on shared relationships and common associations in order to develop a multiscale model of the biology of the host response to TB, constrained by unbiased, high-throughput observations. We therefore propose the time is ripe for the field of TB-OMICS to convene a combined workshop for all groups who have deposited large OMICS data sets to define how to proceed to look for translational outcomes for these data, specifically markers of protection, diagnostics and treatment monitoring.

Acknowledgements

Funding: A Deffur acknowledges funding from the Hasso Plattner Foundation. RJ Wilkinson acknowledges the following funding sources: Wellcome Trust (UK): 084323, 104803; MRC (UK): U1175.02.002.00014; FP7-HEALTH-F3-2013-305578; MRC-SHIP-02-2013. AK Coussens acknowledges funding from Academy of Science of South Africa and MRC-SHIP-02-2013.

Disclosure: The authors declare no conflict of interest.

References

1. WHO. Global Tuberculosis Report 2014. Available online: http://www.who.int/tb/publications/global_report/en/
2. Mistry R, Cliff JM, Clayton CL, et al. Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis. *J Infect Dis* 2007;195:357-65.
3. Jacobsen M, Repsilber D, Gutschmidt A, et al. Candidate biomarkers for discrimination between infection and disease caused by *Mycobacterium tuberculosis*. *J Mol Med (Berl)* 2007;85:613-21.
4. Kim MJ, Wainwright HC, Locketz M, et al. Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. *EMBO Mol Med* 2010;2:258-74.
5. Berry MP, Graham CM, McNab FW, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. *Nature* 2010;466:973-7.
6. Maertzdorf J, Ota M, Repsilber D, et al. Functional correlations of pathogenesis-driven gene expression signatures in tuberculosis. *PLoS One* 2011;6:e26938.
7. Maertzdorf J, Repsilber D, Parida SK, et al. Human gene expression profiles of susceptibility and resistance in tuberculosis. *Genes Immun* 2011;12:15-22.
8. Lesho E, Forestiero FJ, Hirata MH, et al. Transcriptional responses of host peripheral blood cells to tuberculosis

- infection. *Tuberculosis (Edinb)* 2011;91:390-9.
9. Bloom CI, Graham CM, Berry MP, et al. Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy. *PLoS One* 2012;7:e46191.
 10. Ottenhoff TH, Dass RH, Yang N, et al. Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis. *PLoS One* 2012;7:e45839.
 11. Maertzdorf J, Weiner J 3rd, Mollenkopf HJ, et al. Common patterns and disease-related signatures in tuberculosis and sarcoidosis. *Proc Natl Acad Sci U S A* 2012;109:7853-8.
 12. Bloom CI, Graham CM, Berry MP, et al. Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. *PLoS One* 2013;8:e70630.
 13. Cliff JM, Lee JS, Constantinou N, et al. Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. *J Infect Dis* 2013;207:18-29.
 14. Kaforou M, Wright VJ, Oni T, et al. Detection of tuberculosis in HIV-infected and -uninfected African adults using whole blood RNA expression signatures: a case-control study. *PLoS Med* 2013;10:e1001538.
 15. Cai Y, Yang Q, Tang Y, et al. Increased complement C1q level marks active disease in human tuberculosis. *PLoS One* 2014;9:e92340.
 16. Anderson ST, Kaforou M, Brent AJ, et al. Diagnosis of childhood tuberculosis and host RNA expression in Africa. *N Engl J Med* 2014;370:1712-23.
 17. Montoya D, Inkeles MS, Liu PT, et al. IL-32 is a molecular marker of a host defense network in human tuberculosis. *Sci Transl Med* 2014;6:250ra114.
 18. Krutzik SR, Hewison M, Liu PT, et al. IL-15 links TLR2/1-induced macrophage differentiation to the vitamin D-dependent antimicrobial pathway. *J Immunol* 2008;181:7115-20.
 19. Fabri M, Stenger S, Shin DM, et al. Vitamin D is required for IFN-gamma-mediated antimicrobial activity of human macrophages. *Sci Transl Med* 2011;3:104ra102.
 20. Ghesani N, Patrawalla A, Lardizabal A, et al. Increased cellular activity in thoracic lymph nodes in early human latent tuberculosis infection. *Am J Respir Crit Care Med* 2014;189:748-50.
 21. Swindell WR, Johnston A, Voorhees JJ, et al. Dissecting the psoriasis transcriptome: inflammatory- and cytokine-driven gene expression in lesions from 163 patients. *BMC Genomics* 2013;14:527.

Cite this article as: Deffur A, Wilkinson RJ, Coussens AK. Tricks to translating TB transcriptomics. *Ann Transl Med* 2015;3(S1):S43. doi: 10.3978/j.issn.2305-5839.2015.04.12